Connection

Co-Authors

This is a "connection" page, showing publications co-authored by HIROHITO YAMAGUCHI and SEUNG-OE LIM.
Connection Strength

0.437
  1. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
    View in: PubMed
    Score: 0.145
  2. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 2021 04 15; 131(8).
    View in: PubMed
    Score: 0.049
  3. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
    View in: PubMed
    Score: 0.040
  4. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.
    View in: PubMed
    Score: 0.037
  5. GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
    View in: PubMed
    Score: 0.036
  6. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.036
  7. Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. Am J Cancer Res. 2016; 6(3):628-38.
    View in: PubMed
    Score: 0.034
  8. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62.
    View in: PubMed
    Score: 0.034
  9. Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.